Abstract 2494
Background
CAR-T cells are a new cancer treatment, where T cells are taken from the patient and modified in a laboratory to target cancer cells. There have been some promising results from early clinical trials, which have led to two products being made available to patients in the NHS. Axicabtagene ciloleucel for relapsed/refractory B-cell lymphoma patients and tisagenlecleucel for relapsed/refractory B-cell lymphoma patients and relapsed/refractory B-ALL patients under the age of 25. There are multiple clinical trials in progress throughout Europe, mostly in the haematology setting, with some in oncology. There are significant toxicities to this treatment modality and this is a complex heavily pre-treated patient population. Education of the wider nursing and multi professional team is therefore crucial. A new Lecturer Practitioner role was established, to focus on CAR-T. This poster explores nurses’ learning needs associated with introducing CAR-T therapy in a specialist cancer hospital in London, UK.
Methods
Data has been collected through evaluation of previous nursing educational initiatives in CAR-T therapy, which aimed to identify further learning needs. Further data collection is in development.
Results
Although this work is on-going, initial findings indicate that nurses require more education and support particularly around managing toxicities and patient expectations. Challenges for educating nurses also include uncertainties around the long-term effects of this treatment modality.
Conclusions
CAR-T therapy is being implemented at multiple centres throughout the UK/Europe and it is evident that there are a multitude of future opportunities for career development for nurses in this area. The role of a Lecturer Practitioner in CAR-T at a specialist cancer hospital has been created to address some of the educational needs of the nursing and multi-professional team. The post holder is involved in a wide range of educational initiatives, from national bespoke study days and academic cancer care modules to ward based teaching. It is clear that there is a need for a role that combines clinical practice and academia, bridging the theory to practice gap and providing expert clinical knowledge to nurses caring for these patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
R. Ellard: Honoraria (self): MolMed; Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Kite Gilead. All other authors have declared no conflicts of interest.
Resources from the same session
3264 - A novel preclinical model of RAF-independent MEK1 mutant tumors and its treatment with novel ATP competitive MEK inhibitor
Presenter: Luca Hegedus
Session: Poster Display session 3
Resources:
Abstract
4918 - HER2 inhibition in Aggressive Squamous Cell Carcinomas driven by a common MET Sema Domain Polymorphism
Presenter: Nur Afiqah Mohamed Salleh
Session: Poster Display session 3
Resources:
Abstract
2426 - ADAM9 as a target for lung cancer treatment
Presenter: Yuh-pyng Sher
Session: Poster Display session 3
Resources:
Abstract
5537 - Novel polyurea/polyurethane nanocapsules loaded with a tambjamine analog to improve cancer chemotherapy delivery and safety in lung cancer
Presenter: Marta Perez Hernandez
Session: Poster Display session 3
Resources:
Abstract
1597 - Discovery of Clinical Candidate DBPR112, a Furanopyrimidine-based Epidermal Growth Factor Receptor Inhibitor for the Treatment of Non-Small Cell Lung Cancer
Presenter: Hsing-pang Hsieh
Session: Poster Display session 3
Resources:
Abstract
3543 - Molecular characteristics in lung squamous cell carcinomas dependent on TP53 status – putative targets
Presenter: Vilde Haakensen
Session: Poster Display session 3
Resources:
Abstract
4111 - Comparison of molecular profiles between primary tumour and matched metastasis in non-small cell lung cancer
Presenter: Asuka Kawachi
Session: Poster Display session 3
Resources:
Abstract
4559 - Treatment with BLU-667, a potent and selective RET inhibitor, provides rapid clearance of ctDNA in Patients with RET-altered Non-Small Cell Lung Cancer (NSCLC) and Thyroid Cancer
Presenter: Giuseppe Curigliano
Session: Poster Display session 3
Resources:
Abstract
2501 - Triple MET/SRC/PIM inhibition in MET addicted tumors
Presenter: Ilaria Attili
Session: Poster Display session 3
Resources:
Abstract
5655 - Bioactivation of napabucasin triggers reactive oxygen species–mediated cancer cell death
Presenter: Fieke Froeling
Session: Poster Display session 3
Resources:
Abstract